<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02825537</url>
  </required_header>
  <id_info>
    <org_study_id>CVE101-15</org_study_id>
    <nct_id>NCT02825537</nct_id>
  </id_info>
  <brief_title>Study of the Effect of Elastic Compression (French Class III) on Water Balance Change in Healthy Subjects</brief_title>
  <official_title>Study of the Effect of Class III Elastic Venous Compression Focused on 33 mmHg on Water Balance Change in Healthy Subjects. Exploratory, Randomized, Open-label, Controlled and Crossover Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratoires Innothera</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biotrial</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Laboratoires Innothera</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to compare precisely, under standardized test conditions,&#xD;
      water balance changes in healthy subjects with or without the daytime use of compression&#xD;
      stocking.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evolution of the total bodily fluid volume in the daytime sequence measured by impedancemetry with or without daytime use of compression stocking</measure>
    <time_frame>adjusted over 3 consecutive days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evolution of the water balance in daytime sequence,in night sequence and on a 24h sequence with or without daytime use of compression stocking</measure>
    <time_frame>adjusted over 3 consecutive days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the subject's weight (in kilograms), in daytime sequence, in night sequence and on a 24 h sequence with or without daytime use of compression stocking</measure>
    <time_frame>adjusted over 3 consecutive days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the volume of urine determined by weight (in kilograms),in daytime sequence, in night sequence and a 24h sequence with or without daytime use of compression stocking</measure>
    <time_frame>adjusted over 3 consecutive days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution days of the neck circumference (in centimeter) in a dynamic sequence, in supine sequence and on a 24h sequence with or without daytime use of compression stocking</measure>
    <time_frame>adjusted over 3 consecutive days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of leg perimeters (in centimeter) in 3 points in dynamic sequence, in supine sequence , and over 24h sequence with or without daytime use of compression stocking</measure>
    <time_frame>adjusted over 3 consecutive days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the time and volume of the first urine after H0 determined by weight (in kilograms) with or without daytime use of compression stocking</measure>
    <time_frame>adjusted over 3 consecutive days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the quantity of NaCl excreted in urine in daytime sequence, in night sequence, and over 24 h sequence with or without daytime use of compression stocking</measure>
    <time_frame>adjusted over 3 consecutive days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the total bodily fluid volume in night sequence and on a 24h sequence measured by impedancemetry with or without daytime use of compression stocking</measure>
    <time_frame>adjusted over 3 consecutive days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>With use of compression stocking</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Use of compression stocking during 3 consecutives days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Without use of compression stocking</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>No use of compression stocking during 3 consecutives days</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Compression stocking</intervention_name>
    <description>A class III (20 to 36 mm Hg) elastic compression stocking according to the french classification</description>
    <arm_group_label>With use of compression stocking</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No use of compression stocking</intervention_name>
    <description>No use of compression stocking</description>
    <arm_group_label>Without use of compression stocking</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male subject aged 40 years old or more,&#xD;
&#xD;
          2. Subject with a Body Mass Index (BMI) between 18.5 and 30 kg/m²,&#xD;
&#xD;
          3. Subject with a body fat percentage between 11 and 27 % of his weight, as measured by&#xD;
             impedancemetry,&#xD;
&#xD;
          4. Subject with a muscle mass index of less than 55% of his weight, as measured by&#xD;
             impedancemetry,&#xD;
&#xD;
          5. Subject with a water status, as measured by impedancemetry, between + / - 5 liters of&#xD;
             his normal value, as indicated by the impedancemetry,&#xD;
&#xD;
          6. Healthy subject, registered in the French biomedical research volunteer national&#xD;
             database,&#xD;
&#xD;
          7. Subject whose lower limb measurements correspond to the size grid of the compression&#xD;
             stocking used,&#xD;
&#xD;
          8. Subject agreeing to abstain from alcohol intake during all hospitalization periods,&#xD;
&#xD;
          9. Subject practicing under 5 hours of intense physical activity per week, on average, in&#xD;
             the 4 weeks preceding the screening visit (marathon training, military training ...),&#xD;
&#xD;
         10. Subject agreeing to abstain from any strenuous activity , especially sports, from the&#xD;
             screening visit to the end of study (including during the out-patient period),&#xD;
&#xD;
         11. Subject accepting the constraints of the study,&#xD;
&#xD;
         12. Subject being available during the whole period of the study,&#xD;
&#xD;
         13. Subject who has signed the consent form after being adequately informed and receiving&#xD;
             the information sheet,&#xD;
&#xD;
         14. Subject affiliated to the French social security system or receiving benefits of that&#xD;
             type.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Subject who is a smoker or a former smoker who stopped smoking less than 6 months ago,&#xD;
&#xD;
          2. Subject following a salt-free diet,&#xD;
&#xD;
          3. Subject following or planning to follow a diet,&#xD;
&#xD;
          4. Subject having a temperature ≥ 38,5°C in the morning,&#xD;
&#xD;
          5. Subject having, upon clinical examination, a systolic blood pressure (SBP) &lt; 91 mmHg&#xD;
             or &gt; 139 mmHg, a diastolic blood pressure (DBP) &lt; 41 mmHg or &gt; 89 mmHg, or a heart&#xD;
             rate (HR) &lt; 40 bpm or &gt; 100 bpm, and judged clinically significant by the&#xD;
             investigator,&#xD;
&#xD;
          6. Subject having an intestinal transit disorder that disrupts hydroelectric balance,&#xD;
&#xD;
          7. Alcohol-dependent subject or subject with a positive alcohol breath test,&#xD;
&#xD;
          8. Subject having a localized or general edema (a simple evening edema of the legs or&#xD;
             ankles is accepted for inclusion),&#xD;
&#xD;
          9. Subject suffering from insulin-dependent or uncontrolled diabetes (controlled diabetes&#xD;
             is accepted),&#xD;
&#xD;
         10. Subject with a serious, stabilized, or progressive illness (as judged by the&#xD;
             investigator),&#xD;
&#xD;
         11. Subject with hypertension or heart failure,&#xD;
&#xD;
         12. Subject with known renal function disorders,&#xD;
&#xD;
         13. Subject with known liver failure,&#xD;
&#xD;
         14. Subject with venous insufficiency of clinical class C3, C4, C5 or C6 according to the&#xD;
             Clinical / Etiological / Anatomical / Pathophysiological (CEAP) classification,&#xD;
&#xD;
         15. Subject following long-term therapy with diuretics, nonsteroidal anti-inflammatory&#xD;
             drugs (NSAIDs), steroids, nutritional supplements or opiates,&#xD;
&#xD;
         16. Subject having, upon questioning or clinical examination, advanced peripheral&#xD;
             neuropathy, skin infections, eczematous dermatitis, or weeping skin disorder of the&#xD;
             leg,&#xD;
&#xD;
         17. Subject with a medical contraindication to compression therapy according to the&#xD;
             interview or clinical examination: phlegmatia coerulea dolens, septic thrombosis,&#xD;
             intolerance to the product including the self-supporting band, allergic reaction to&#xD;
             any component, arteritis obliterans of lower limbs, advanced diabetic microangiopathy,&#xD;
&#xD;
         18. Subject with active implants, such as a pacemaker or other mechanical heart device ,&#xD;
             and non-active implants, for example a hip prosthesis (dental implants are&#xD;
             authorized),&#xD;
&#xD;
         19. Subject who is participating in another clinical trial or who is in the exclusion&#xD;
             period from a previous study,&#xD;
&#xD;
         20. Person deprived of freedom by judicial or administrative decision, or a person&#xD;
             hospitalized without their consent,&#xD;
&#xD;
         21. Subject of legal age who is protected by law or under guardianship,&#xD;
&#xD;
         22. Subject with a current mental or psychiatric disorder or a history of mental or&#xD;
             psychiatric disorder, or any other factor limiting the collection of informed consent,&#xD;
&#xD;
         23. Person who works for the Contract Research Organisation or for Innothéra laboratories,&#xD;
             or has a dependent relationship with these entities.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hakim Charfi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Biotrial</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Biotrial</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>June 30, 2016</study_first_submitted>
  <study_first_submitted_qc>July 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 7, 2016</study_first_posted>
  <last_update_submitted>August 23, 2016</last_update_submitted>
  <last_update_submitted_qc>August 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

